Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,465.50GBp
9:38am EDT
Change (% chg)

11.50 (+0.79%)
Prev Close
1,454.00
Open
1,457.50
Day's High
1,466.67
Day's Low
1,455.50
Volume
3,024,112
Avg. Vol
8,800,743
52-wk High
1,745.56
52-wk Low
1,444.00

Select another date:

Wed, Sep 20 2017

BRIEF-Theravance Biopharma highlights positive results from impact study of Trelegy Ellipta

* Theravance Biopharma highlights positive headline results from impact study of Trelegy Ellipta announced by Glaxosmithkline and Innoviva

BRIEF-GlaxoSmithkline and Innoviva announces positive impact results for Trelegy in COPD

* CO, INNOVIVA REPORT POSITIVE HEADLINE RESULTS FROM STUDY SHOWING SINGLE INHALER TRIPLE THERAPY TRELEGY ELLIPTA REDUCED COPD EXACERBATIONS

GlaxoSmithKline breathes easier as U.S. approves triple lung drug

LONDON U.S. regulators have approved GlaxoSmithKline's three-in-one inhaler for chronic lung disease, a key new product for the group as it strives to keep its lead in respiratory medicine despite falling sales of the older drug Advair.

UPDATE 1-GlaxoSmithKline breathes easier as U.S. approves triple lung drug

* CEO sees it as one of three "critical" new drug launches (Adds detail on competition, analyst reaction, shares)

U.S. FDA approves GSK's three-in-one drug inhaler for COPD

GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD).

U.S. FDA approves GSK's three-in-one drug inhaler for COPD

Sept 18 GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD).

France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus

PARIS French biotech company Neovacs is confident that its experimental drug to treat lupus could grab significant market share from standard treatments of the auto-immune disease, its chief executive said.

France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus

PARIS, Sept 15 French biotech company Neovacs is confident that its experimental drug to treat lupus could grab significant market share from standard treatments of the auto-immune disease, its chief executive said.

BRIEF-GSK gets EU greenlight for self-injectable version of lupus drug

* GSK RECEIVES CHMP POSITIVE OPINION FOR SELF-INJECTABLE FORMULATION OF BENLYSTA FOR SYSTEMIC LUPUS ERYTHEMATOSUS

GSK's three-in-one inhaler gets positive opinion from EU agency

GlaxoSmithKline said on Friday that a European Medicines Agency (EMA) panel has recommended the company's three-in-one inhaled lung drug.

Select another date: